2024 Press Releases 2024 2023 2022 2021 2020 Portfolio Companies New Leaf Portfolio Companies Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility AnalysisSeptember 3, 2024 Iterum Therapeutics Broadens Patent Estate for Oral SulopenemAugust 2, 2024 Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research CollaborationAugust 1, 2024 TigerConnect Dominates G2’s Summer 2024 Rankings, Securing Top Positions in Healthcare TechnologyJuly 30, 2024 Iterum Therapeutics Commences Rights OfferingJuly 22, 2024 Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 PatientsJuly 16, 2024 Transparency with Kyruus HealthJuly 16, 2024 Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT Trial)June 27, 2024 Star Therapeutics Presents Clinical Data for VGA039, a Subcutaneous Therapy for the Treatment of Von Willebrand Disease (VWD)June 26, 2024 Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract InfectionsJune 21, 2024 Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2June 21, 2024 Electra Therapeutics Presents Late-Breaking Clinical Data at EHA2024 from Ongoing Phase 1b Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)June 16, 2024 COGENT BIOSCIENCES ANNOUNCES ADDITIONAL CLINICAL DATA FROM PART 1 OF ITS ONGOING SUMMIT TRIAL EVALUATING BEZUCLASTINIB IN PATIENTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS (NONADVSM)June 14, 2024 Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)May 16, 2024 Truveris Secures $15 Million in Series E Funding Through Canaan Partners and New Leaf Venture PartnersMay 14, 2024 BrightInsight Expands its Partnership with Google Cloud to Enhance the Patient Journey Through Generative AIMay 7, 2024 Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 BillionApril 29, 2024 Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral SulopenemApril 29, 2024 Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate CancerApril 11, 2024 Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)April 10, 2024 Merck Completes Acquisition of Harpoon Therapeutics, IncMarch 11, 2024 CuraSen Therapeutics Announces Oral Presentation of Additional Positive Phase 2a Data with CST-2032/CST-107 in Patients with Alzheimer’s or Parkinson’s Disease at AD/PD™ 2024 International ConferenceMarch 7, 2024 New Data Demonstrate Sunbird Bio’s APEX Diagnostic Test Accurately Differentiates Key Alzheimer’s Disease Biomarker in Blood March 5, 2024 Cleerly® Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging SystemMarch 5, 2024 COGENT BIOSCIENCES ANNOUNCES POSITIVE PART 1B DATA FROM SUMMIT TRIAL EVALUATING BEZUCLASTINIB IN PATIENTS WITH NONADVANCED SYSTEMIC MASTOCYTOSISFebruary 22, 2024 Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative DiseaseFebruary 20, 2024 New collaboration with Kyruus Health to advance care access and outcomes for patients at Nicklaus Children’s Health SystemFebruary 14, 2024 COGENT BIOSCIENCES ANNOUNCES OVERSUBSCRIBED $225 MILLION PRIVATE PLACEMENTFebruary 14, 2024 TigerConnect is a 2024 Best in KLAS Award Winner for Clinical CommunicationsFebruary 7, 2024 Bluesight Demonstrates Industry-Leading Performance in Drug Diversion Detection; New Data Highlights 6.6X Advantage Over CompetitorsFebruary 7, 2024 Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast CancerFebruary 6, 2024 Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology PipelineJanuary 8, 2024
